Orange Book product · Generic (ANDA)
PAZOPANIB HYDROCHLORIDE
PAZOPANIB HYDROCHLORIDE
Generic (ANDA)ANDA 219034TE ABRX EUGIA PHARMA
At a glance
Dec 04, 2024
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 04, 2024
1 yr 7 mo ago
Today
Pharmaceutical detail
Active ingredient
PAZOPANIB HYDROCHLORIDE
Strength
EQ 200MG BASE
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 219034
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of PAZOPANIB HYDROCHLORIDE
- 2009VOTRIENTBrand (NDA)
NDA 022465 · NOVARTIS
- 2025PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 219922 · TORRENT
- 2024PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 218231 · NOVUGEN
- 2023PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 217713 · APOTEX
- 2023PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 215837 · SUN PHARM
- 2023PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 217517 · TEVA PHARMS INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
